# EXPRESS SCRIPTS FORMULARY ANALYSIS: 2025 → 2026


Generated: 2025-12-23 19:56:56
Mode: pdf_direct
Source: express_scripts_2025.pdf (22 pages)
        express_scripts_2026.pdf (22 pages)

--------------------------------------------------------------------------------

# Express Scripts National Preferred Formulary: 2025 vs 2026 Comparison

## Executive Summary

The 2026 formulary reflects significant year-over-year changes including **biosimilar preference shifts**, **new drug additions**, **expanded exclusions**, and **notable brand-to-biosimilar transitions**. Key themes include aggressive biosimilar adoption (particularly in inflammatory conditions and oncology), removal of several specialty medications, and tightening of generic-only coverage in multiple therapeutic classes.

---

## 1. Drug Additions to 2026 Formulary

### New Specialty/Brand Medications Added

| Drug Name                            | Therapeutic Class                      | Notes                                                  |
| ------------------------------------ | -------------------------------------- | ------------------------------------------------------ |
| **ANDEMBRY AUTOINJECTOR** [INJ] [SP] | Hereditary Angioedema                  | New preferred HAE agent                                |
| **ANZUPGO** [SP]                     | Not specified                          | New specialty addition                                 |
| **AVSOLA** [INJ] [SP]                | TNF Antagonist (Infliximab biosimilar) | **Major change**: Now preferred over INFLECTRA         |
| **AVTOZMA IV** [INJ] [SP]            | Tocilizumab biosimilar                 | New preferred tocilizumab                              |
| **BILDYOS** [INJ] [SP]               | Osteoporosis                           | New bone modifier                                      |
| **BILPREVDA** [INJ] [SP]             | Bone Mineral Density                   | New addition                                           |
| **DOPTELET SPRINKLE** [SP]           | Thrombocytopenia                       | Expanded formulation                                   |
| **HERCESSI** [INJ] [SP]              | Trastuzumab biosimilar                 | **Now preferred** over KANJINTI/TRAZIMERA              |
| **HYMPAVZI PEN** [INJ] [SP]          | Hemophilia                             | Renamed/reformulated                                   |
| **INFLIXIMAB** [INJ] [SP]            | TNF Antagonist                         | Generic infliximab now preferred                       |
| **INGREZZA, INGREZZA SPRINKLE** [SP] | Movement Disorders                     | **Major addition** - was not on 2025 formulary         |
| **INVEGA HAFYERA** [INJ]             | Antipsychotic                          | Added to formulary                                     |
| **INVEGA SUSTENNA** [INJ]            | Antipsychotic                          | Added to formulary                                     |
| **INVEGA TRINZA** [INJ]              | Antipsychotic                          | Added to formulary                                     |
| **OGIVRI** [INJ] [SP]                | Trastuzumab biosimilar                 | Now preferred                                          |
| **OTEZLA XR** [SP]                   | Inflammatory Conditions                | Extended-release formulation added                     |
| **RHAPSIDO**                         | Not specified                          | New addition                                           |
| **SPRAVATO** [SP]                    | Depression                             | **Major addition** - moved from exclusion to formulary |
| **TRUEPLUS LANCETS** [OTC]           | Diabetic Supplies                      | New preferred lancet                                   |
| **TYVASO** [SP]                      | PAH                                    | Added (previously only TYVASO DPI)                     |
| **TYRUKO** [INJ] [SP]                | Multiple Sclerosis                     | New natalizumab biosimilar                             |

---

## 2. Drug Removals from 2026 Formulary

### Medications Removed/Now Excluded

| Drug Name                    | Therapeutic Class           | 2026 Status                                           |
| ---------------------------- | --------------------------- | ----------------------------------------------------- |
| **ACTEMRA** [INJ] [SP]       | Tocilizumab                 | **Excluded** - replaced by AVTOZMA IV, TYENNE IV      |
| **ARNUITY ELLIPTA**          | Pulmonary Anti-Inflammatory | Now excluded                                          |
| **AUSTEDO, AUSTEDO XR** [SP] | Movement Disorders          | **Excluded** - replaced by INGREZZA                   |
| **BYDUREON BCISE** [INJ]     | GLP-1 Agonist               | Removed                                               |
| **BYETTA** [INJ]             | GLP-1 Agonist               | Removed                                               |
| **CYLTEZO** [INJ] [SP]       | Adalimumab biosimilar       | **Excluded** for inflammatory conditions              |
| **EPIPEN, EPIPEN JR** [INJ]  | Epinephrine                 | Removed (generic preferred)                           |
| **HYSINGLA ER**              | Opioid                      | Removed                                               |
| **INFLECTRA** [INJ] [SP]     | Infliximab biosimilar       | **Excluded** - replaced by AVSOLA, generic infliximab |
| **KANJINTI** [INJ] [SP]      | Trastuzumab biosimilar      | **Excluded** - replaced by HERCESSI, OGIVRI           |
| **OCALIVA** [SP]             | Liver Disease               | Removed                                               |
| **OMNIPOD GO: PODS**         | Insulin Pump                | Removed                                               |
| **OXYCONTIN**                | Opioid                      | **Excluded**                                          |
| **RASUVO** [INJ]             | Methotrexate                | Now excluded                                          |
| **STELARA** [INJ] [SP]       | Ustekinumab                 | **Excluded effective July 1, 2026**                   |
| **SYMFI LO** [SP]            | HIV                         | Removed                                               |
| **SYMJEPI** [INJ]            | Epinephrine                 | Removed                                               |
| **SYMLINPEN** [INJ]          | Diabetes                    | Removed                                               |
| **TRACLEER SUSPENSION** [SP] | PAH                         | Removed                                               |
| **TRAZIMERA** [INJ] [SP]     | Trastuzumab biosimilar      | **Excluded**                                          |
| **TRUETRACK** [OTC]          | Test Strips                 | Removed from preferred                                |

---

## 3. Major Biosimilar/Generic Preference Changes

### TNF Antagonists (Infliximab)

| 2025 Preferred | 2026 Preferred               | 2026 Excluded                  |
| -------------- | ---------------------------- | ------------------------------ |
| INFLECTRA      | AVSOLA, INFLIXIMAB (generic) | INFLECTRA, REMICADE, RENFLEXIS |

### Trastuzumab Products

| 2025 Preferred      | 2026 Preferred   | 2026 Excluded                                      |
| ------------------- | ---------------- | -------------------------------------------------- |
| KANJINTI, TRAZIMERA | HERCESSI, OGIVRI | HERCEPTIN, KANJINTI, TRAZIMERA, HERZUMA, ONTRUZANT |

### Tocilizumab Products

| 2025 Preferred        | 2026 Preferred        | 2026 Excluded            |
| --------------------- | --------------------- | ------------------------ |
| ACTEMRA IV, TYENNE IV | AVTOZMA IV, TYENNE IV | ACTEMRA IV, TOFIDENCE IV |
| ACTEMRA SC            | TYENNE SC             | ACTEMRA SC               |

### Ustekinumab Products (Major Change)

| 2025 Status                | 2026 Status                                               |
| -------------------------- | --------------------------------------------------------- |
| STELARA SC/IV on formulary | **STELARA SC excluded effective July 1, 2026**            |
|                            | STELARA IV excluded                                       |
|                            | Preferred: IMULDOSA, SELARSDI, USTEKINUMAB-TTWE, YESINTEK |

---

## 4. New Exclusions Added for 2026

### Autonomic & Central Nervous System

| New Exclusion             | Preferred Alternative                                        |
| ------------------------- | ------------------------------------------------------------ |
| **AUSTEDO, AUSTEDO XR**   | tetrabenazine, INGREZZA, INGREZZA SPRINKLE                   |
| **NOURIANZ**              | cabergoline, entacapone, pramipexole, rasagiline, ropinirole |
| **BREKIYA**               | dihydroergotamine nasal spray, triptans                      |
| **AMPHETAMINE ER ODT**    | dextroamphetamine er, lisdexamfetamine                       |
| **ZANAFLEX 8MG CAPSULES** | tizanidine                                                   |
| **EXXUA ER**              | Generic Antidepressant Agents                                |
| **ZURNAI**                | naloxone nasal spray or syringes, KLOXXADO                   |

### Cardiovascular

| New Exclusion              | Preferred Alternative                       |
| -------------------------- | ------------------------------------------- |
| **telmisartan/amlodipine** | amlodipine/olmesartan, amlodipine/valsartan |
| **triamterene, DYRENIUM**  | amiloride hcl, eplerenone, spironolactone   |

### Dermatological

| New Exclusion                   | Preferred Alternative                                   |
| ------------------------------- | ------------------------------------------------------- |
| **EPSOLAY**                     | azelaic acid, ivermectin, metronidazole, FINACEA FOAM   |
| **TWYNEO**                      | adapalene, benzoyl peroxide, clindamycin, tretinoin     |
| **ciclopirox 8% treatment kit** | ciclopirox 8% topical solution, tavaborole              |
| **naftifine, NAFTIN**           | ciclopirox, clotrimazole, econazole cream, ketoconazole |

### Diabetes

| New Exclusion    | Preferred Alternative            |
| ---------------- | -------------------------------- |
| **BRYNOVIN**     | saxagliptin, JANUVIA             |
| **HUMALOG VIAL** | HUMALOG KWIKPEN, INSULIN LISPRO  |
| **KIRSTY**       | HUMALOG, INSULIN LISPRO, LYUMJEV |

### Ear/Nose

| New Exclusion                       | Preferred Alternative                                                    |
| ----------------------------------- | ------------------------------------------------------------------------ |
| **azelastine/fluticasone, DYMISTA** | azelastine nasal plus flunisolide/fluticasone/mometasone nasal or XHANCE |

### Endocrine

| New Exclusion | Preferred Alternative |
| ------------- | --------------------- |
| **SEPHIENCE** | sapropterin           |

### Gastrointestinal

| New Exclusion      | Preferred Alternative              |
| ------------------ | ---------------------------------- |
| **opium tincture** | diphenoxylate/atropine, loperamide |

### Hematological

| New Exclusion | Preferred Alternative                    |
| ------------- | ---------------------------------------- |
| **WAYRILZ**   | eltrombopag, DOPTELET, NPLATE, TAVALISSE |

### Miscellaneous

| New Exclusion          | Preferred Alternative                |
| ---------------------- | ------------------------------------ |
| **SOLIRIS, ULTOMIRIS** | ENSPRYNG, EPYSQLI                    |
| **DAWNZERA**           | ANDEMBRY, HAEGARDA, TAKHZYRO         |
| **YIMMUGO**            | GAMMAGARD LIQUID, GAMUNEX-C, XEMBIFY |
| **TREXALL**            | methotrexate tablets                 |
| **OTREXUP, RASUVO**    | methotrexate injection               |
| **ZEPBOUND VIALS**     | liraglutide, WEGOVY, ZEPBOUND PENS   |

### Obstetrical & Gynecological

| New Exclusion           | Preferred Alternative                      |
| ----------------------- | ------------------------------------------ |
| **paroxetine mesylate** | paroxetine hcl, paroxetine hcl ext-release |

### Oncology

| New Exclusion       | Preferred Alternative                             |
| ------------------- | ------------------------------------------------- |
| **JOBEVNE**         | ZIRABEV                                           |
| **BEIZRAY/ALBUMIN** | docetaxel                                         |
| **AVGEMSI**         | gemcitabine                                       |
| **HERNEXEOS**       | Coverage may be approved under certain conditions |
| **UNLOXCYT**        | KEYTRUDA, LIBTAYO                                 |
| **VABRINTY**        | ELIGARD, FIRMAGON, LUPRON DEPOT                   |
| **PHYRAGO**         | dasatinib                                         |

### Ophthalmic

| New Exclusion                          | Preferred Alternative                |
| -------------------------------------- | ------------------------------------ |
| **tafluprost drops, travoprost drops** | bimatoprost drops, latanoprost drops |
| **TRAVATAN Z, ZIOPTAN**                | bimatoprost drops, latanoprost drops |
| **pilocarpine 1.25% drops, VIZZ**      | No alternatives recommended          |

### Renal

| New Exclusion | Preferred Alternative                               |
| ------------- | --------------------------------------------------- |
| **VELPHORO**  | calcium acetate, lanthanum, sevelamer carbonate/hcl |

### Respiratory

| New Exclusion           | Preferred Alternative                           |
| ----------------------- | ----------------------------------------------- |
| **ARNUITY ELLIPTA**     | ASMANEX HFA, ASMANEX TWISTHALER, QVAR REDIHALER |
| **FLUTICASONE ELLIPTA** | ASMANEX HFA, ASMANEX TWISTHALER, QVAR REDIHALER |

### Antiinfectives

| New Exclusion                     | Preferred Alternative                                                                 |
| --------------------------------- | ------------------------------------------------------------------------------------- |
| **fosfomycin, BLUJEPA, ORLYNVAH** | amoxicillin, cephalexin, ciprofloxacin, nitrofurantoin, sulfamethoxazole/trimethoprim |
| **penciclovir cream, DENAVIR**    | acyclovir, famciclovir, valacyclovir                                                  |

---

## 5. Restrictions Removed/Coverage Expanded

| Drug                               | Change                                    |
| ---------------------------------- | ----------------------------------------- |
| **SPRAVATO**                       | Moved from exclusion to formulary         |
| **INVEGA HAFYERA/SUSTENNA/TRINZA** | Added to formulary (previously excluded)  |
| **INGREZZA**                       | Added as preferred for movement disorders |
| **OGIVRI**                         | Now preferred trastuzumab biosimilar      |

---

## 6. Therapeutic Class Changes Summary

### Inflammatory Conditions (IACCV Program)

**Major biosimilar shifts:**
- **CYLTEZO** moved from preferred to excluded
- **ADALIMUMAB-RYVK (by Teva)** now excluded (Quallent version still preferred)
- **ACTEMRA SC** excluded, replaced by **TYENNE SC**
- **STELARA SC** excluded effective July 1, 2026

### Movement Disorders
- **AUSTEDO/AUSTEDO XR** excluded
- **INGREZZA/INGREZZA SPRINKLE** now preferred

### Antipsychotics (Injectable)
- Long-acting injectables (INVEGA products) added to formulary
- Previous exclusion of INVEGA HAFYERA removed

### Oncology - Trastuzumab
- Complete preference shift from KANJINTI/TRAZIMERA to HERCESSI/OGIVRI

### Complement Inhibitors
- **SOLIRIS and ULTOMIRIS** now excluded
- **EPYSQLI** remains preferred

---

## 7. Diabetic Supplies Changes

| Category          | 2025                        | 2026                    |
| ----------------- | --------------------------- | ----------------------- |
| Preferred Lancets | DROPLET, MICROLET, TECHLITE | Added: TRUEPLUS LANCETS |
| Test Strips       | TRUETRACK included          | TRUETRACK removed       |
| Insulin Vials     | HUMALOG VIAL covered        | HUMALOG VIAL excluded   |

---

## 8. Specification/Strength Restrictions Tightened

| Drug                            | 2025              | 2026                                                       |
| ------------------------------- | ----------------- | ---------------------------------------------------------- |
| **bupropion ext-release**       | All strengths     | Only 150mg, 300mg specified                                |
| **citalopram**                  | All forms         | tablets, solution only (capsules excluded)                 |
| **escitalopram**                | All forms         | tablets, solution only (capsules excluded)                 |
| **dicyclomine**                 | All strengths     | 10mg, 20mg only (40mg excluded)                            |
| **glimepiride**                 | All strengths     | 1mg, 2mg, 4mg only (3mg excluded)                          |
| **glipizide**                   | All strengths     | 5mg, 10mg only (2.5mg excluded)                            |
| **glucagon emergency kit**      | All manufacturers | All except Fresenius                                       |
| **labetalol**                   | All strengths     | 100mg, 200mg, 300mg only (400mg excluded)                  |
| **meclizine**                   | All strengths     | 12.5mg, 25mg only (50mg excluded)                          |
| **meloxicam**                   | All forms         | capsules, tablets only (suspension excluded)               |
| **metaxalone**                  | All strengths     | 400mg, 800mg only (640mg excluded)                         |
| **metformin**                   | All strengths     | 500mg, 750mg, 850mg, 1000mg only (625mg excluded)          |
| **methocarbamol**               | All strengths     | 500mg, 750mg only (1000mg excluded)                        |
| **methylphenidate ext-release** | All strengths     | Excludes 45mg, 63mg (previously also 72mg)                 |
| **metronidazole**               | All strengths     | 250mg, 500mg tablets only (125mg excluded)                 |
| **ondansetron ODT**             | All strengths     | 4mg, 8mg only (16mg excluded)                              |
| **oxycodone**                   | All forms         | capsules, uncoated tablets only                            |
| **quetiapine**                  | All strengths     | Except 150mg                                               |
| **rabeprazole**                 | All forms         | delayed-release tablets only (sprinkle excluded)           |
| **topiramate**                  | All forms         | ext-release, tablets only (50mg sprinkle excluded)         |
| **tramadol**                    | All strengths     | 50mg, 100mg only                                           |
| **zolpidem**                    | All forms         | ext-release, tablets, sl tablets (7.5mg capsules excluded) |

---

## 9. Key Administrative/Policy Changes

1. **STELARA Transition**: Continuation of therapy applies through June 30, 2026; excluded for all utilizers effective July 1, 2026

2. **Inflammatory Conditions Program**: Note added that "PDL and product placement for treatment of Inflammatory and Atopic Conditions in the IACCV Program are subject to change throughout the year"

3. **Document Reference**: 2025 referenced "For One Touch Diabetic Supplies, see Exclusion Document" while 2026 references "For Stelara, see Exclusion Document"

4. **Terminology Updates**: 
   - "drug list (formulary)" changed to "prescription drug list (PDL)"
   - "drugs" changed to "medications" throughout
   - "doctor" changed to "physician"
   - "copayments" changed to "copays"
   - "member ID card" changed to "prescription ID card"

---

## 10. Impact Summary by Therapeutic Area

| Therapeutic Area            | Net Impact       | Key Changes                              |
| --------------------------- | ---------------- | ---------------------------------------- |
| **Inflammatory Conditions** | Major disruption | STELARA exclusion, biosimilar shifts     |
| **Oncology**                | Significant      | Trastuzumab biosimilar preference change |
| **Movement Disorders**      | Major            | AUSTEDO→INGREZZA switch                  |
| **Complement Inhibitors**   | Major            | SOLIRIS/ULTOMIRIS exclusion              |
| **Antipsychotics**          | Positive         | INVEGA LAIs added                        |
| **Depression**              | Positive         | SPRAVATO added                           |
| **Diabetes**                | Minor            | Insulin vial restrictions                |
| **Ophthalmology**           | Moderate         | Prostaglandin restrictions               |
| **Respiratory**             | Moderate         | Inhaler preference changes               |

---

## Recommendations for Plan Sponsors

1. **Communicate STELARA transition** to affected members well in advance of July 1, 2026 deadline
2. **Review AUSTEDO utilization** and prepare transition plans to INGREZZA
3. **Update prior authorization criteria** for newly excluded medications
4. **Monitor biosimilar adoption** in oncology (trastuzumab) and inflammatory conditions
5. **Assess cost impact** of complement inhibitor exclusions (SOLIRIS/ULTOMIRIS)